American Century Companies’s MapLight Therapeutics MPLT Stock Holding History

American Century Companies’s Portfolio MPLT Stock Details MPLT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$268K	Buy	+7,470	New	+$215K	﹤0.01%	2727

Other funds holding MPLT

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

American Century Companies's MPLT Position: Q2 2026 in Review

American Century Companies opened a new position in MapLight Therapeutics (MPLT) in Q2 2026: 7,470 shares worth $268K. The stake represents ﹤0.01% of the portfolio and ranks #2727 among its holdings.

100 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

American Century Companies held 7,470 shares of MapLight Therapeutics worth $268K as of Q2 2026.
MapLight Therapeutics was a new American Century Companies position in Q2 2026.
MapLight Therapeutics made up ﹤0.01% of American Century Companies's portfolio in Q2 2026, its #2727 holding.
100 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on American Century Companies's 13F filing for Q2 2026, filed 12 Aug 2026.